Kiora Pharmaceuticals, Inc. (KPRX)Healthcare | Biotechnology | Encinitas, United States | NasdaqCM
2.52 USD
+0.03
(1.205%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 2.53 +0.01 (0.397%) ⇧ (April 17, 2026, 7:34 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:06 a.m. EDT
Kiora (KPRX) is showing sharp short-term momentum following $24M in secured milestone-based financing, which fuels a buy narrative for calls; however, the underlying fundamentals remain weak with negative forward earnings and cash burn, offering a questionable long-term case absent further clinical data success, and provide no dividend yield. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052067 |
| AutoETS | 0.067839 |
| AutoARIMA | 0.067840 |
| MSTL | 0.073491 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 8% |
| H-stat | 7.47 |
| Ljung-Box p | 0.003 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 9.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.284 |
| Market Cap | 11,060,532 |
| Forward P/E | -1.13 |
| Beta | -0.77 |
| Previous Name | EyeGate Pharmaceuticals, Inc. |
| Website | https://www.kiorapharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12195122 |
| Address1 | 332 Encinitas Boulevard |
| Address2 | Suite 102 |
| All Time High | 145,800.0 |
| All Time Low | 1.765 |
| Ask | 2.59 |
| Ask Size | 1 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 2,858,780 |
| Average Daily Volume3 Month | 503,332 |
| Average Volume | 503,332 |
| Average Volume10Days | 2,858,780 |
| Beta | -0.774 |
| Bid | 2.47 |
| Bid Size | 1 |
| Book Value | 4.287 |
| City | Encinitas |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.52 |
| Current Ratio | 5.989 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.5755 |
| Day Low | 2.4301 |
| Debt To Equity | 2.284 |
| Display Name | Kiora Pharmaceuticals |
| Dividend Date | 1,567,123,200 |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -9,434,446 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.717 |
| Enterprise Value | -6,765,237 |
| Eps Forward | -2.23 |
| Eps Trailing Twelve Months | -2.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.135 |
| Fifty Day Average Change | 0.385 |
| Fifty Day Average Change Percent | 0.18032786 |
| Fifty Two Week Change Percent | -12.195122 |
| Fifty Two Week High | 4.18 |
| Fifty Two Week High Change | -1.6599998 |
| Fifty Two Week High Change Percent | -0.39712918 |
| Fifty Two Week Low | 1.765 |
| Fifty Two Week Low Change | 0.755 |
| Fifty Two Week Low Change Percent | 0.42776203 |
| Fifty Two Week Range | 1.765 - 4.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,423,837,800,000 |
| Float Shares | 3,828,949 |
| Forward Eps | -2.23 |
| Forward P E | -1.1300448 |
| Free Cashflow | -9,187,735 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -3,714,160 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0308 |
| Held Percent Institutions | 0.18478 |
| Implied Shares Outstanding | 4,389,100 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,718,064,000 |
| Last Split Factor | 1:9 |
| Long Business Summary | Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. |
| Long Name | Kiora Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 11,060,532 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_27817978 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -10,835,154 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,060,529 |
| Number Of Analyst Opinions | 1 |
| Open | 2.47 |
| Operating Cashflow | -9,961,176 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 224 9600 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.39682502 |
| Post Market Price | 2.53 |
| Post Market Time | 1,776,468,881 |
| Prev Name | EyeGate Pharmaceuticals, Inc. |
| Previous Close | 2.49 |
| Price Hint | 4 |
| Price To Book | 0.5878236 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.619 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.03 |
| Regular Market Change Percent | 1.20482 |
| Regular Market Day High | 2.5755 |
| Regular Market Day Low | 2.4301 |
| Regular Market Day Range | 2.4301 - 2.5755 |
| Regular Market Open | 2.47 |
| Regular Market Previous Close | 2.49 |
| Regular Market Price | 2.52 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 33,302 |
| Return On Assets | -0.19466999 |
| Return On Equity | -0.51736 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,389,099 |
| Shares Percent Shares Out | 0.0043 |
| Shares Short | 16,951 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,131 |
| Short Name | Kiora Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0044 |
| Short Ratio | 0.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | KPRX |
| Target High Price | 12.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 12.0 |
| Total Cash | 17,089,084 |
| Total Cash Per Share | 4.326 |
| Total Debt | 368,259 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.37983 |
| Two Hundred Day Average Change | 0.1401701 |
| Two Hundred Day Average Change Percent | 0.05889921 |
| Type Disp | Equity |
| Volume | 33,302 |
| Website | https://www.kiorapharma.com |
| Zip | 92,024 |